aTyr Pharma, Inc. Total Liabilities
aTyr Pharma, Inc. total liabilities. Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) has total liabilities worth $26.88 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are aTyr Pharma, Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of aTyr Pharma, Inc. (2012–2025)
Total liabilities of aTyr Pharma, Inc. from 2012 to 2025. This chart illustrates how aTyr Pharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
aTyr Pharma, Inc. Competitors by Total Liabilities
The table below lists competitors of aTyr Pharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Winsome Resources Ltd
AU:WR1
|
Australia | AU$18.66 Million |
|
Namsun Alumini
KO:008350
|
Korea | ₩156.93 Billion |
|
Seanergy Maritime Holdings Corp
F:RHSR
|
Germany | €291.90 Million |
|
Thinkific Labs Inc
TO:THNC
|
Canada | CA$19.80 Million |
|
Inspired Entertainment Inc
NASDAQ:INSE
|
USA | $408.50 Million |
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
Germany | €98.81 Million |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
USA | $8.96 Million |
|
Guerbet S. A.
PA:GBT
|
France | €669.94 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down aTyr Pharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ATYR total assets.
Liquidity & Leverage Metrics
aTyr Pharma, Inc. Total Liabilities Ratios Explained
aTyr Pharma, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how aTyr Pharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual total liabilities of aTyr Pharma, Inc. from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.88 Million | -0.46% |
| 2024-12-31 | $27.00 Million | -10.55% |
| 2023-12-31 | $30.18 Million | +23.19% |
| 2022-12-31 | $24.50 Million | +282.19% |
| 2021-12-31 | $6.41 Million | -11.47% |
| 2020-12-31 | $7.24 Million | -52.24% |
| 2019-12-31 | $15.16 Million | -20.60% |
| 2018-12-31 | $19.10 Million | -23.95% |
| 2017-12-31 | $25.11 Million | +41.68% |
| 2016-12-31 | $17.72 Million | +21.18% |
| 2015-12-31 | $14.62 Million | -86.90% |
| 2014-12-31 | $111.65 Million | +5.47% |
| 2013-12-31 | $105.87 Million | +1113.25% |
| 2012-12-31 | $8.73 Million | -- |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more